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ABSTRACT 
Polymorphisms in the gene that encodes the metabolic enzyme of valproic acid are one of the important factors associated with 
interindividual variability in the effective dose and concentration of the drug. UGT1A6 as the encoding gene of glucuronidase 
enzyme is responsible for valproic acid metabolism, and polymorphisms can therefore influence the drug effectiveness and 
plasma concentration. This study aimed to analyze the allele frequency distribution of UGT1A6 rs6759892 T>G gene that 
encodes the metabolic enzyme of VPA among healthy respondents of Javanese as the largest ethnic group in Indonesia. This 
study used stored biological specimens in the form of DNA isolates from 100 healthy adult respondents who met the inclusion 
criteria. Genotyping of UGT1A6 rs6759892 gene was performed using PCR-RFLP method with 5'-
CTGACACGGCCATAGTTGGT-3' forward primer and 5'-CCAGCAGCTTGTCACCTACA-3' reverse primer. The results 
showed that the frequencies of T allele and G allele of UGT1A6 rs6759892 among Javanese population in Indonesia were 0.86 
and 0.14, respectively. The frequency of G allele in Javanese-Indonesian ethnic population is similar to that found in a study 
involving Chinese, Caucasian, and African populations. This study recommends further analysis regarding the influence of such 
SNP on the pharmacokinetic variability of VPA and its clinical response. Analysis of such correlation as a risk factor for cancer 
is also required as an effort to seek an early and effective preventive therapy. 
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INTRODUCTION 
  
Epilepsy is the most common chronic neurological disorder 
affecting approximately 50 million people worldwide. This 
neurological disease is characterized by unexpected and 
periodic seizure incidence (Löscher et al, 2009). In developing 
countries such as Indonesia, the prevalence is higher 
compared to developed countries, ranging from 5 to 74 per 
1000 people. To date, anti-epileptic drugs (AEDs) remain a 
popular choice of therapy (PERDOSSI, 2014). 
 Valproic acid (VPA; 2-propylpentanoic acid) is one of the 
most widely used anti-epileptic drugs to control various types 
of seizure, including myoclonic, absent, general, and partial 
seizures in both adult and pediatric patients since they have 
the lowest adverse effects with a broad therapeutic index (Zhu 
et al, 2017). VPA is also known as a therapy for bipolar 
disorder, migraine, neuropathic pain, and cancer (Luís et al, 
2011). However, interindividual variability in its dose and 
plasma concentration still occurs. A study of 208 adult patients 
with epilepsy showed an average variability of the required 
VPA dose of up to 10-fold (Blanco-Serrano et al, 1999). In 
addition, the incidence of life-threatening adverse drug 
reactions (ADR), such as hepatotoxicity, teratogenic effects, 
and pancreatitis which correlate with the drug concentration 
in the blood, reinforces the importance of pharmacogenetic 
testing along with TDM services in VPA therapy (Gervasini 
et al, 2010). It is acknowledged that one of the factors 
influencing the variability is the genetic polymorphisms in the 
metabolic enzyme-encoding gene that has been proven to 
correlate with its pharmacodynamic and pharmacokinetic 
variability [Zhu et al, 2017; Nagar et al, 2004). 
 An understanding of the mechanism of VPA metabolism 
can explain the influence of genetic polymorphisms on the 
changes in plasma concentration and their clearance with an 
implication for the effective dose. VPA metabolism has three 
main routes including 2 metabolic pathways of phase I, 
namely β-oxidation in the liver mitochondria as well as 
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enzymes (CYP) in the liver endoplasmic reticulum. The third 
metabolic pathway is phase II metabolism through the 
formation of glucuronate conjugates by glucuronidase, an 
enzyme encoded by UGT1A6 gene and one of the most 
commonly-found enzymes compared to other UGT1A 
isoforms (Owens et al, 2005) in the liver endoplasmic 
reticulum. This third pathway becomes the major route of 
valproic acid, accounting for 30-50% dose (Hung et, 2011; 
Balestrini and Sisodiya, 2017). Such process of conjugation 
reaction takes place through the transfer of UDPG1cA to VPA 
aglycones to form β-glucuronide with a high polarity structure 
that facilitates its renal excretion (Guillemette, 2003; Goey et 
al, 2016). A previous study found 3 SNPs in UGT1A6 gene, 
including rs6759892, rs2070959, and rs1105879 with the 
highest mutant allele frequencies in rs6759892 among 
Chinese population, and these three alleles correlated with 
lower VPA concentration in the blood, thus requiring a higher 
dose (Guo et al, 2012).  
 This present research was part of the pharmacogenetic 
studies of VPA use among Indonesian population suffering 
from epilepsy. Analysis of genetic variants in target genes that 
encode VPA metabolism enzymes is essential to provide 
information on the profile of genetic variations in Indonesian 
population of which implications for individual therapeutic 
dose and response to the use of VPA as the first line 
antiepileptic drug for several types of seizure can be further 
studied (Zhu et al, 2017).  This study therefore aimed to 
determine the allele frequency distribution of UGT1A6 
rs6759892 T>G gene in Javanese population as the largest 
ethnic group in Indonesia. 
    
 
MATERIALS AND METHODS 
 
Research Subjects: This study used the stored biological 
samples of DNA isolated from 3 ml of the blood of 100 
healthy respondents from a previous study. Respondents were 
categorized as originated in Javanese ethnic group determined 
by their 3 previous generations.  
 
Ethical considerations: This study has passed the ethical 
review from the Ethics Committee of the Faculty of Medicine 
of Universitas Islam Indonesia with the protocol No. 
43/Ka.Kom.Et/70/KE/XI/2018. 
 
Genotyping of UGT1A6 rs6759892 T>G: Genotype analysis 
of UGT1A6 rs6759892 T>G was performed using the PCR 
method with 5'-CTGACACGGCCATAGTTGGT-3' as the 
forward primer and 5'-CCAGCAGCTTGTCACCTACA-3' as 
the reverse primer prior to the process of Restriction Length 
Fragment Polymorphism (RLFP). The conditions for PCR 
amplification were initial denaturation at 94°C for 45 seconds, 
34 cycles of denaturation at 94°C for 30 seconds, annealing at 
57°C for 30 seconds, and extension at 72°C for 50 seconds as 
well as final extension at 72°C for 3 minutes. The 
amplification products (305 bp) were then identified in 1.5% 
agarose gel electrophoresis for 30 minutes with a voltage of 
100 V followed by restriction digestion using Hha1 enzyme 
and incubation at 37oC for 1 hour. Hha1 enzyme cut the 
sequence of GCGC into 233 DNA templates. GG genotype 
was recognized and digested by Hha1 enzyme. The digestion 
products were then analyzed using 3% agarose gel 
electrophoresis for 90 minutes with a voltage of 70 V. The 
digestion of amplification products resulted in 305 bp 
fragments of TT genotype (wild type) and 233 bp and 72 bp 
fragments of GG genotype (mutant) with 305 bp, 233 bp, and 
72 bp for heterozygotes (TG). 
 Univariate data analysis was then used to determine the 
allele frequencies of UGT1A6 rs6759892 T>G gene. Allele 
frequencies were calculated using the Hardy-Weinberg 
equation as in the previous study with the following formula 
Oussalah et al, 2015). 
 
T Allele = 
(TT Genotype x 2)+ TG Genotype
2 x number of samples
 
G Allele = 
(GG Genotiype x 2)+ TG Genotype





There were 100 healthy Javanese-Indonesian respondents 
involved in the genotyping of UGT1A6 rs6759892 T>G with 
equal numbers of male and female respondents. The 
characteristics of the research subjects are presented in Table 
1. The electrophoretic display of digestion by the enzyme that 




Table 1.  
Characteristics of the subjects involved in the genotyping of 
UGT1A6 rs6759892 gene 
Patient characteristic Male (n=50) Female (n=50) 
Average age (years) 21.26±1.21 21.14±1.43 
Average BMI (kg/m2) 22.734.0±9 21.49±3.41 
Genotype of UGT1A6 rs6759892 T>G 
TT 41 36 
TG 7 12 
GG 2 2 
 
In addition, to identify the allele frequencies of UGT1A6 
rs6759892 T>G in both male and female groups, a descriptive 
analysis was performed, and the results are displayed in Table 
2. 
Table 2.  
Allele frequencies of UGT1A6 rs6759892 based on gender 
Allele Variant Male (%) Female (%) 
T Allele 0.89 0.84 
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Figure 1.  
Region cutting by Hha1 restriction enzyme as the detector of polymorphisms in UGT1A6 rs6759892 T>G gene 
Note: lane M = marker/ladder of 50 bp; lane C = negative control/undigested products/PCR products; lane A1 = samples with 
wild type (TT genotype); lane C1 and E1 = samples with heterozygote (TG genotype); lane B1 and D1 = samples with 
mutant/homozygote (GG genotype) 
DISCUSSION 
 
It is acknowledged that one of the main enzymes for valproic 
acid metabolism typically expressed in the liver is the 
glucuronidase enzyme with an amino acid length of 531, 
encoded by UGT1A6 gene. This enzyme exists not only in the 
liver but also in various organs, such as the bile, colon, 
stomach, and brain, and it becomes a catalyst in 
glucuronidation reactions, including in both endogenous 
substrates such as steroids and exogenous substrates including 
a number of drugs like valproic acid (Nagar et al, 2004) 
UGT1A6 is a major isoform of UGT enzyme. Interindividual 
variability in a glucuronidase process mediated by this enzyme 
can have essential pharmacological and therapeutic 
consequences (Chatzistefanidis  et al 2012).  
 Genotypic analysis of glucuronidase enzyme-encoding 
gene can provide important basic information for the 
development and implementation of genetic screening in 
therapeutic decision making and become the basis for 
"individualized medication" particularly when calculating the 
need for effective individual dose in VPA therapy. 
 The lowest frequency of GG variant in both male and 
female respondents was found to be identical in this study 
(2%). The lowest proportion of homozygotes was also found 
in a study involving 94 Chinese patients with epilepsy (6.4%) 
(Guo et al, 2012). Similarly, some studies involving 162 
healthy adult Chinese volunteers, 190 healthy Taiwanese 
subjects, and 162 adult Taiwanese patients with epilepsy 
revealed that their frequencies of GG genetic variant were 
0.62%, 4.74%, and 6.79%, respectively (Hung et al, 2011; 
Kua et al, 2012). A percentage of less than 10% was also 
found among Greek pediatric and adult patients with epilepsy 
(5.22% vs 7.46%) (Chatzistefanidis et al, 2016). Meanwhile, 
3 other studies of healthy subjects involving German, Indian 
population and case-control studies involving German-
Finnish-Swedish population each showed a higher frequency 
of GG genetic variant of 17.20%, 16.3%, and 19.7%, 
respectively (Jain et al, 2015; Justenhoven et al, 2013; 
MARIE-GENICA, 2012). As it was expected, the findings of 
this study confirmed previous research related to similar 
frequencies of genetic variations between Javanese-
Indonesian population and Chinese population as opposed to 
other populations (Ningrum et al, 2018; 2019). This underpins 
the significance of genetic testing to be considered in drug 
selection as well as in determination of safe and effective dose 
among races-populations that have almost never been 
involved in clinical trials of new FDA-approved drugs, such 
as among Indonesian population. 
 The highest proportion of alleles in UGT1A6 rs6759892 
in this study is T allele (> 80%) in both male and female 
patients. A study using human liver bank as the modeling 
system showed that gender differences did not correlate with 
the level of UGT gene expressions, but using enzyme inducer 
drugs, smoking, and drinking alcohol were proved to be the 
factors associated with increased UGT activity [24]. 
Therefore, differences in gender proportions in a 
pharmacogenomic study analyzing the influence of 
polymorphisms on proteins that encode UGT enzymes can be 
ignored, or no matching techniques are required by these 
factors in the data analysis. 
 Several studies have been carried out to analyze the 
influence of genetic variation of UGT1A6 gene, an isoform 
with the second most variability of activities after UGT1A1 
(Court 2010)), on interindividual pharmacokinetics of VPA 
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therapy. A study involving 98 pediatric patients with epilepsy 
who received VPA showed that polymorphisms in UGT1A6 
affected its biotransformation, leading to lower plasma 
concentration of VPA, and implied the need for dose increase 
(Hung et al, 2016; Guo et al, 2012). 
 It is acknowledged that the type of genetic variation in 
UGT1A6 rs6759892 gene is single nucleotide polymorphisms 
(SNP) with two variations in the form of intron variant 
polymorphism and variant of amino acid coding sequences 
(exon). The variant that changes the activity of glucuronidase 
enzyme is the polymorphisms in amino acid coding sequences 
that transform thymine nucleotide base (T) into guanine (G) 
which change the formation of codons from TCA (encoding 
the serine amino acid - Ser) into GCA (encoding the alanine 
amino acid - Ala). Serine is located in the 7th amino acid of the 
allosteric site of glucuronidase enzyme, while the active site 
of the enzyme is in the amino acids Glu451, Tyr504, and 
Asn450 (Nagar et al, 2004). Changes in the structure of amino 
acid sequences in glucuronidase enzyme from serine into 
alanine are assumed to result in 2-fold increase in enzyme 
activity, thus leading to a higher level of catalyst function in 
the metabolic process (Krishnaswamy et al, 2005). 
 A study involving 162 Chinese patients (36.23 ± 1.02 
years old) with epilepsy found that among the 6 gene 
candidates studied, polymorphisms in UGT1A6 gene 
significantly correlated with changes in valproic acid plasma 
concentration (LnCDR/ln concentration to dose ratio). 
Patients with UGT1A6 rs6759892 allele variant tended to 
have lower LnCDR (3.88 ± 0.41; 3.70 ± 0.47 days/ml) 
compared to the other groups (4.22 ± 0.45 days/ml). In 
addition, patients with homozygous variants also had lower 
LnCDR (3.70 ± 0.47 days/ml) compared to those in the 
heterozygous variant group (3.88 ± 0.41 days/ml). These 
results indicate that the polymorphisms in UGT1A6 
rs6759892 gene correlate with the decreased plasma 
concentration of VPA and thus influence the dose to generate 
the expected biological response (Hung et al, 2011). In 
addition, a study of 98 Chinese patients with epilepsy (7.8 ± 
7.5 years old) found a significantly higher plasma 
concentration of VPA in the group of patients with double 
heterozygotes on UGT1A6 (Guo et al 2012). 
 This study is part of the pharmacogenomic study of anti-
epileptic drug therapy for Indonesian patients, in which a 
study of patients with epilepsy is performed to provide an 
approach to the individual therapeutic dose of anti-epileptic 
drugs, including VPA. Not only related to the variability of 
VPA metabolism, polymorphisms in UGT1A6 rs6759892 
T>G gene are also proven to be one of the risk factors for 
cancer and other pathological conditions. Two population-
based case-control studies revealed that subjects with GG 
genotype correlated with an increased risk of breast cancer 
with 1.17 OR (MARIE-GENICA, 2012). This was also 
confirmed through the pooled analysis of a study involving 
7148 subjects with cancer and 8720 control subjects from 
Finland, Germany, and Sweden with 1.09 OR (Justenhoven et 
al, 2013). Although UGT1A6 has a low activity towards 
estrogen and its carcinogenic metabolites, it is suspected that 
the polymorphisms of such gene are also related to its activity 
to metabolize exogenous carcinogens (Hu et al 2014). In 
addition, the UGT1A6 rs6759892 Ser7.Ala variant showed an 
increased risk of gallstone-related cholecystectomy with 3.88 
OR among geriatric patients involved in a cohort study with 
773 Italian patients (Oussalah et al 2015). This is likely 
because UGT1A6 polymorphisms disrupt the process of 
inactivation in several endogenous and exogenous molecules, 
including bilirubin. It is necessary to acknowledge that there 
was a contradictory report about changes in UGT enzyme 
activity due to UGT1A6 polymorphisms. In addition to 
changes in enzyme activity, mRNA degradation might be 
involved in the variability of its activity (Kua et al, 2012). 
 Meanwhile, there was a contradictory study related to 
how UGT1A6 rs6759892 polymorphisms were associated 
with VPA biotransformation and its plasma concentration in 
134 patients (43.3% of whom were pediatric patients) 
(Chatzistefanidis et al, 2016) and the difference between non-
optimum UGT expression in infants and children as opposed 
to that of adult patients probably became the reason for this 
contradictive finding. Transition of VPA metabolic pathways 
particularly through mitochondria and CYP in children 
increased the risk of VPA toxicity due to higher concentration 
of 4-ene-VPA metabolites (Anderson, 2002; Ghodke-Puranik 
2013). Therefore, studies of the influence of polymorphisms 
on UGT encoding genes involving pediatric patients are more 
appropriately associated with variability in the prevalence of 
VPA toxicity instead of variations in dose requirement which 
is probably more suitable with the use of polymorphism-free 
variables in CYP metabolic pathway or mitochondrial β-
oxidation. 
 In conclusion, the research on the allele frequency of 
UGT1A6 gene involving Javanese-Indonesian population has 
a novelty value in the preliminary pharmacogenetic study of 
the use of valproic acid since it has never been performed in 
previous studies. The frequency of G allele of UGT1A6 
rs6759892 among Javanese population in Indonesia was 0.14 
(4%). Therefore, this research recommends further studies 
regarding the influence of these polymorphisms on the 
pharmacokinetic profile of VPA as well as the clinical 
response to valproic acid among Indonesian patients with 
epilepsy. Further studies related to its influence on the risk of 
breast cancer, the most common type of cancer among 
Indonesian women, are also suggested to encourage earlier 
health promotion and prevention programs. 
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